mds
Showing 26 - 50 of 108
MDS Trial in France (transplantation)
Active, not recruiting
- MDS
- transplantation
-
Amiens, France
- +36 more
Jul 4, 2022
Myeloproliferative Tumor, Chronic Neutrophilic Leukemia, MDS Trial in Tampa (Fedratinib Pill)
Recruiting
- Myeloproliferative Neoplasm
- +2 more
- Fedratinib Pill
-
Tampa, FloridaMoffitt Cancer Center
Jun 15, 2022
MDS, MDS Trial in France (Luspatercept Injection [Reblozyl], Eprex)
Recruiting
- MDS
- Myelodysplastic Syndromes
- Luspatercept Injection [Reblozyl]
- Eprex
-
Amiens, France
- +30 more
May 19, 2022
AML, B-ALL, T-ALL Trial in Memphis (CD123-CAR T, Cyclophosphamide, Fludarabine)
Recruiting
- AML
- +4 more
- CD123-CAR T
- +4 more
-
Memphis, Tennessee
- +1 more
May 10, 2022
AML, ALL, MDS Trial in New York (Clofarabine, Fludarabine, Busulfan)
Recruiting
- AML
- +8 more
- Clofarabine
- +5 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 13, 2022
Familial Investigations of Childhood Cancer Predisposition
Recruiting
- Acute Leukemia
- +45 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 11, 2022
Relapsed/Refractory AML, AML, Adult, MDS Trial in United States (NKX101 - CAR NK cell therapy)
Recruiting
- Relapsed/Refractory AML
- +3 more
- NKX101 - CAR NK cell therapy
-
Denver, Colorado
- +6 more
Apr 8, 2022
AML, MDS Trial in Tianjin (SHR-1702)
Active, not recruiting
- AML
- MDS
-
Tianjin, Tianjin, ChinaBlood disease hospital of Chinese Academy of Medical Sciences
Mar 7, 2022
AML, Adult Recurrent, MDS Trial in Durham (DVX201)
Recruiting
- AML, Adult Recurrent
- MDS
- DVX201
-
Durham, North CarolinaDuke University Hospital
Feb 11, 2022
AML, MDS Trial in United States (APVO436)
Recruiting
- AML
- MDS
- APVO436
-
San Francisco, California
- +11 more
Feb 8, 2022
National Longitudinal Cohort of Hematological Diseases
Recruiting
- Multiple Myeloma
- +17 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jan 11, 2022
Optimize Treatment Strategies for Older Hematologic Malignancies
Recruiting
- Leukemia, Acute
- MDS
- Bone Marrow or Peripheral Blood Graft (BMT)
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jan 7, 2022
AML, MDS, Old Age; Debility Trial in Suzhou (Azacitidine, all trans retinoic acid)
Recruiting
- AML
- +3 more
- Azacitidine
- all trans retinoic acid
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 27, 2021
Acute Myelogenous Leukemia, AML, Advanced MDS Trial in Miami (Pevonedistat, Cytarabine)
Completed
- Acute Myelogenous Leukemia
- +3 more
-
Miami, FloridaUniversity of Miami
Dec 7, 2021
Leukemia, Lymphoma, Multiple Myeloma Trial in Omaha (CHAMPS-II adapted to adults 60+ years in HCT setting, Survivorship
Recruiting
- Leukemia
- +4 more
- CHAMPS-II adapted to adults 60+ years in HCT setting
- Survivorship education active control
-
Omaha, NebraskaUniversity of Nebraska Medical Center
Nov 26, 2021
GVHD, AML, ALL Trial in Boston (FLUDARABINE, CYCLOPHOSPHAMIDE, TBI)
Recruiting
- GVHD
- +15 more
- FLUDARABINE
- +6 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 30, 2021
MDS Trial in Beijing (Hetrombopag, Stanozolol Tablets)
Not yet recruiting
- MDS
- Hetrombopag
- Stanozolol Tablets
-
Beijing, ChinaPeking Union Medical College Hospital
Sep 18, 2021
AML, Adult, MDS Trial in Lørenskog (Standard therapy, Precision therapy)
Recruiting
- AML, Adult
- MDS
- Standard therapy
- Precision therapy
-
Lørenskog, NorwayAkershus Universitetssykehus
Aug 23, 2021
AML, ALL, MDS Trial in Germany (Peripheral blood stem cells)
Recruiting
- AML
- +2 more
- Peripheral blood stem cells
-
Bonn, Germany
- +8 more
Aug 25, 2021
Optical Genome Mapping in Hematological Malignancies
Recruiting
- MDS
- +2 more
-
Brest, France
- +3 more
Aug 16, 2021
AML, MDS Trial in Belgium, United States (NKR-2)
Completed
- AML
- MDS
- NKR-2
-
Aurora, Colorado
- +6 more
Apr 30, 2021
P53 Mutation, Myeloid Malignancy, MDS Trial in Shanghai (Decitabine, Arsenic Trioxide)
Recruiting
- P53 Mutation
- +3 more
- Decitabine
- Arsenic Trioxide
-
Shanghai, Shanghai, ChinaHematological department, Shanghai Institute of Hematology, Ruij
Apr 20, 2021